國立虎尾科技大學 |

Total Synthesis of Natural Products with Antimicrobial Activity

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Total Synthesis of Natural Products with Antimicrobial Activity/ by Andrew Giltrap.
Author:	Giltrap, Andrew.
Description:	XXIV, 268 p. 144 illus., 59 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Medicinal chemistry. -
Online resource:	https://doi.org/10.1007/978-981-10-8806-3
ISBN:	9789811088063

Total Synthesis of Natural Products with Antimicrobial Activity
Giltrap, Andrew.

Total Synthesis of Natural Products with Antimicrobial Activity[electronic resource] /by Andrew Giltrap. - 1st ed. 2018. - XXIV, 268 p. 144 illus., 59 illus. in color.online resource. - Springer Theses, Recognizing Outstanding Ph.D. Research,2190-5053. - Springer Theses, Recognizing Outstanding Ph.D. Research,.

Introduction -- Total Synthesis of Teixobactin -- Synthesis of Deshydroxy Skyllamycins A-C -- Total Synthesis of Skyllamycins A-C -- Experimental.

This thesis focuses on the development of efficient and scalable total syntheses of natural products that can be used as preferred scaffolds for anti-infective drug discovery. It describes the total synthesis of two classes of antimicrobial non-ribosomal peptides (NRPs) – teixobactin and the skyllamycins – with subsequent biological evaluation. The first part describes the first total synthesis of teixobactin by means of a solid-phase peptide synthesis-macrolactamisation approach, yielding a synthetic natural product that can combat a number of clinically relevant Gram-positive bacterial pathogens. The second part describes the first total synthesis of skyllamycins A-C, a family of structurally complex cyclic NRPs, which inhibit the growth of the Pseudomonas aeruginosa biofilms that are responsible for significant mortality among cystic fibrosis patients.

ISBN: 9789811088063

Standard No.: 10.1007/978-981-10-8806-3doiSubjects--Topical Terms:

1253747
Medicinal chemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

Total Synthesis of Natural Products with Antimicrobial Activity
LDR:02473nam a22004095i 4500 001 993055
003 DE-He213
005 20200702175556.0
007 cr nn 008mamaa
008 201225s2018 si | s |||| 0|eng d
020 $a 9789811088063 $9 978-981-10-8806-3
024 7 $a 10.1007/978-981-10-8806-3 $2 doi
035 $a 978-981-10-8806-3
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 615.19 $2 23
100 1 $a Giltrap, Andrew. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1203506
245 1 0 $a Total Synthesis of Natural Products with Antimicrobial Activity $h [electronic resource] / $c by Andrew Giltrap.
250 $a 1st ed. 2018.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2018.
300 $a XXIV, 268 p. 144 illus., 59 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Springer Theses, Recognizing Outstanding Ph.D. Research, $x 2190-5053
505 0 $a Introduction -- Total Synthesis of Teixobactin -- Synthesis of Deshydroxy Skyllamycins A-C -- Total Synthesis of Skyllamycins A-C -- Experimental.
520 $a This thesis focuses on the development of efficient and scalable total syntheses of natural products that can be used as preferred scaffolds for anti-infective drug discovery. It describes the total synthesis of two classes of antimicrobial non-ribosomal peptides (NRPs) – teixobactin and the skyllamycins – with subsequent biological evaluation. The first part describes the first total synthesis of teixobactin by means of a solid-phase peptide synthesis-macrolactamisation approach, yielding a synthetic natural product that can combat a number of clinically relevant Gram-positive bacterial pathogens. The second part describes the first total synthesis of skyllamycins A-C, a family of structurally complex cyclic NRPs, which inhibit the growth of the Pseudomonas aeruginosa biofilms that are responsible for significant mortality among cystic fibrosis patients.
650 0 $a Medicinal chemistry. $3 1253747
650 0 $a Medical biochemistry. $3 1254555
650 0 $a Drug resistance. $3 872072
650 1 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Drug Resistance. $3 782695
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811088056
776 0 8 $i Printed edition: $z 9789811088070
776 0 8 $i Printed edition: $z 9789811342455
830 0 $a Springer Theses, Recognizing Outstanding Ph.D. Research, $x 2190-5053 $3 1253569
856 4 0 $u https://doi.org/10.1007/978-981-10-8806-3
912 $a ZDB-2-CMS
912 $a ZDB-2-SXC
950 $a Chemistry and Materials Science (SpringerNature-11644)
950 $a Chemistry and Material Science (R0) (SpringerNature-43709)